Literature DB >> 19870221

FURTHER OBSERVATIONS ON THE CULTIVATION OF VACCINE VIRUS FOR JENNERIAN PROPHYLAXIS IN MAN.

T M Rivers1, S M Ward.   

Abstract

A dermal strain of vaccine virus has been passed through 99 successive culture passages. This procedure led to a diminution in the pathogenicity of the active agent for the rabbit. By repeated testicular passages in rabbits, however, the virus regained its pathogenicity for that host. New cultures were initiated with the revived virus. A culture strain of virus that has been twice revived in this manner has remained fairly stable for the rabbit through 60 culture passages and it produces mild, yet effective vaccinal reactions in man. Virus in early cultures was not attenuated for man, but later cultures of the original strain and cultures of the 2nd and 3rd revived strains produced mild reactions without fever and discomfort to the patients. Intradermal vaccinations with the culture virus are safe and satisfactory. With the culture virus 118 infants and children have been inoculated and in 100 of them a positive reaction occurred. The culture virus produced a refractory state to a standard dermal strain of calf lymph and vice versa. Culture virus stored in 50 per cent neutral glycerol at -10 degrees C. or at +3 degrees C. maintained a considerable amount of its activity for at least 1 year. Desiccated culture virus sealed in tubes maintained some of its activity when stored at 37 degrees C. for 5 weeks. Fresh cultures can be initiated without difficulty from desiccated virus or from virus that has been stored with or without glycerol.

Entities:  

Year:  1933        PMID: 19870221      PMCID: PMC2132320          DOI: 10.1084/jem.58.5.635

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  3 in total

1.  OBSERVATIONS CONCERNING THE PERSISTENCE OF LIVING CELLS IN MAITLAND'S MEDIUM FOR THE CULTIVATION OF VACCINE VIRUS.

Authors:  T M Rivers; E Haagen; R S Muckenfuss
Journal:  J Exp Med       Date:  1929-07-31       Impact factor: 14.307

2.  CULTIVATION OF VACCINE VIRUS.

Authors:  C P Li; T M Rivers
Journal:  J Exp Med       Date:  1930-09-30       Impact factor: 14.307

3.  CULTIVATION OF VACCINE VIRUS FOR JENNERIAN PROPHYLAXIS IN MAN.

Authors:  T M Rivers
Journal:  J Exp Med       Date:  1931-09-30       Impact factor: 14.307

  3 in total
  17 in total

1.  Attenuation of foot-and-mouth disease virus by chemical means.

Authors:  R Maes
Journal:  Arch Gesamte Virusforsch       Date:  1970

2.  Properties of the CV1 strain of vaccinia virus. I. Studies in cell culture.

Authors:  T J John
Journal:  Arch Gesamte Virusforsch       Date:  1969

3.  Properties of the CV1 strain of vaccinia virus. 3. Sensitivity to thiosemicarbazone.

Authors:  T J John
Journal:  Arch Gesamte Virusforsch       Date:  1969

4.  Properties of the CV1 strain of vaccinia virus. II. Studies in eggs and mice.

Authors:  T J John
Journal:  Arch Gesamte Virusforsch       Date:  1969

5.  The wet preservation of vaccinia virus.

Authors:  L W Greenham
Journal:  Arch Gesamte Virusforsch       Date:  1966

Review 6.  Vaccinia virus: a suitable vehicle for recombinant vaccines?

Authors:  C Kaplan
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  AMOUNT AND DURATION OF IMMUNITY INDUCED BY INTRADERMAL INOCULATION OF CULTURED VACCINE VIRUS.

Authors:  T M Rivers; S M Ward; R D Baird
Journal:  J Exp Med       Date:  1939-05-31       Impact factor: 14.307

8.  JENNERIAN PROPHYLAXIS BY MEANS OF INTRADERMAL INJECTIONS OF CULTURE VACCINE VIRUS.

Authors:  T M Rivers; S M Ward
Journal:  J Exp Med       Date:  1935-09-30       Impact factor: 14.307

9.  COMPARATIVE VIRULENCE OF ST. LOUIS ENCEPHALITIS VIRUS CULTURED WITH BRAIN TISSUE FROM INNATELY SUSCEPTIBLE AND INNATELY RESISTANT MICE.

Authors:  L T Webster; M S Johnson
Journal:  J Exp Med       Date:  1941-10-31       Impact factor: 14.307

10.  THE EFFECT OF PROLONGED CULTIVATION IN VITRO UPON THE PATHOGENICITY OF YELLOW FEVER VIRUS.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.